利妥昔单抗联合来氟米特治疗类风湿关节炎:随机安慰剂对照研究者发起临床试验(AMARA研究)
AMARA研究是一项研究者发起的随机双盲安慰剂对照3期试验,纳入140例对来氟米特应答不足且失败过≥1种DMARD的RA患者,按2:1随机接受利妥昔单抗1000mg(第1、15天)或安慰剂,联合持续口服来氟米特。主要终点第24周ACR50应答率差异未达统计学显著(27% vs 15%,P=0.081),但第16周ACR50及第12-24周ACR20等次要终点显著优于安慰剂;两组不良事件率相似(71% vs 70%),但利妥昔单抗组严重不良事件率更高(20% vs 2%),主要为感染和肌肉骨骼疾病。
要点
- 主要终点第24周ACR50应答率差异未达显著(27% vs 15%,P=0.081)。
- 第16周ACR50(32% vs 15%,P=0.020)及第12-24周ACR20等次要终点显著获益。
- 利妥昔单抗组严重不良事件率更高(20% vs 2%),主要为感染和肌肉骨骼疾病。
核心结论
- 主要终点未达到,但利妥昔单抗联合来氟米特在次要终点上相较于来氟米特单药显示出临床获益。
- 联合治疗总体耐受性尚可,但与更多严重不良事件相关,需要监测。
研究设计与样本
- 研究者发起的随机、双盲、安慰剂对照3期试验,计划样本量因非研究者可控因素未达到。
- 2010年8月13日至2015年1月28日,140例对来氟米特应答不足且失败过≥1种DMARD的RA患者按2:1随机接受利妥昔单抗1000mg(第1、15天静脉给药,n=93)或安慰剂(n=47),联合持续口服来氟米特。
主要发现
- 第16周ACR50应答率利妥昔单抗组32% vs 安慰剂组15%(P=0.020),差异显著。
- 第24周ACR50应答率(主要终点)利妥昔单抗组27% vs 安慰剂组15%(P=0.081),差异未达显著。
- 包括第12至24周ACR20应答率在内的部分次要终点显著 favouring 利妥昔单抗联合来氟米特组。
- 利妥昔单抗组与安慰剂组不良事件率相似(71% vs 70%),但利妥昔单抗组严重不良事件率更高(20% vs 2%),主要为感染和肌肉骨骼疾病。
关键数值与推荐
- 主要疗效终点为第24周ACR50应答率差异(P ≤ 0.025)。
- 次要终点包括ACR20/70应答、更早时间点的ACR50应答及不良事件率。
临床怎么用
- 对于来氟米特应答不足且失败过≥1种DMARD的RA患者,利妥昔单抗联合来氟米特可在部分次要终点(如早期ACR50、ACR20)显示临床获益。
- 联合治疗需监测严重不良事件,尤其是感染和肌肉骨骼疾病。
局限性
- 计划样本量因非研究者可控因素未达到。
- 主要终点第24周ACR50应答率差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of rituximab + LEF in patients with RA. METHODS: In this investigator-initiated, randomized, double-blind, placebo-controlled phase 3 trial, patients with an inadequate response to LEF who had failed one or more DMARD were randomly assigned 2:1 to i.v. rituximab 1000 mg or placebo on day 1 and 15 plus ongoing oral LEF. The primary efficacy outcome was the difference between ≥50% improvement in ACR criteria (ACR50 response) rates at week 24 (P ≤ 0.025). Secondary endpoints included ACR20/70 responses, ACR50 responses at earlier timepoints and adverse event (AE) rates. The planned sample size was not achieved due to events beyond the investigators' control. RESULTS: Between 13 August 2010 and 28 January 2015, 140 patients received rituximab (n = 93) or placebo (n = 47) plus ongoing LEF. Rituximab + LEF resulted in an increase in the ACR50 response rate that was significant at week 16 (32 vs 15%; P = 0.020), but not week 24 (27 vs 15%; P = 0.081), the primary endpoint. Significant differences favouring the rituximab + LEF arm were observed in some secondary endpoints, including ACR20 rates from weeks 12 to 24. The rituximab and placebo arms had similar AE rates (71 vs 70%), but the rituximab arm had a higher rate of serious AEs (SAEs 20 vs 2%), primarily infections and musculoskeletal disorders. CONCLUSION: The primary endpoint was not reached, but rituximab + LEF demonstrated clinical benefits vs LEF in secondary endpoints. Although generally well tolerated, the combination was associated with additional SAEs and requires monitoring. TRIAL REGISTRATION: EudraCT: 2009-015950-39; ClinicalTrials.gov: NCT01244958.
引用
- Behrens F, Koehm M, Rossmanith T, et al. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology (Oxford). 2021. PMID: 33738492. doi:10.1093/rheumatology/keab153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。